Dana-Farber Cancer Institute
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Dana-Farber Cancer Institute sits in the top decile of US sponsors by registered trial count (#42 of 15,742 sponsors by registered trial count).
Dana-Farber Cancer Institute: 781 sponsored US clinical trials, 112 recruiting.
Dana-Farber Cancer Institute sponsors 781 registered US clinical trials on ClinicalTrials.gov, 112 of them currently recruiting, and 449 completed. 15 of these trials are in Phase 3-4 (later-stage) and 492 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 53 trials.
Top-decile sponsor footprint
Dana-Farber Cancer Institute ranks in the top decile of sponsors by registered trial count (#42 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
449 of 537 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (83.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
781 total, page 3 of 16
Osimertinib In EGFR Mutant Lung Cancer
NCT03586453
Liquid Biopsy in Ewing Sarcoma and Osteosarcoma as a Prognostic And Response Diagnostic: LEOPARD
NCT06068075
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
NCT03310879
Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL
NCT03319901
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
NCT03113643
Hereditary Risk Factors for Thyroid Cancer
NCT02747888
Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM
NCT02287428
Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
NCT02269592
Vitamin D in Patients With Stage I-III Colon Cancer or Resectable Colon Cancer Liver Metastases
NCT02172651
A Prospective Study of Plasma Genotyping as a Noninvasive Biomarker for Genotype-directed Cancer Care
NCT02279004
Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies
NCT00131014
Understanding Chronic Lymphocytic Leukemia
NCT04028531
Impact of Exercise Intensity on Cardiac Health in Young Adult Survivors of Childhood Cancer: The PULSE Trial
NCT07442578
Better Real-time Information on Documentation of Goals of Care for Engagement in Serious Illness Communication
NCT07147023
177LuPSMA in Renal Cell Carcinoma
NCT06964958
Pilot of a Trial Enrollment Diversity Dashboard
NCT06795139
Sexual Health and Rehabilitation Online (SHAREonline)
NCT06458049
PRISM for Depression and Anxiety in Young Adults With Cancer
NCT06502483
Exercise for Tumor Suppressive Impact in Black Men With Prostate Cancer on Active Surveillance: The REMOVE Trial
NCT05918263
TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer
NCT06001762
CAR- PRISM (PRecision Intervention Smoldering Myeloma)
NCT05767359
STOP-HER2: Stopping Trastuzumab in HER2+ MBC
NCT05721248
Pathways to Advance Targeted and Helpful Serious Illness Conversations (PATH-SIC)
NCT05629065
Testing Home-based Exercise Strategies in Underserved Minority Cancer Patients Undergoing Chemotherapy: the THRIVE Study
NCT05327452
Personalized Neoantigen Cancer Vaccine + Pembrolizumab After Rituximab for Follicular Lymphoma
NCT03361852
RCT of CBD for Anxiety in Advanced Breast Cancer
NCT04482244
The Effect of Yoga on Nerve Pain Caused by Chemotherapy (Chemotherapy-Induced Peripheral Neuropathy)
NCT05121558
Venetoclax Plus Inotuzumab for B-ALL
NCT05016947
Copanlisib Plus Venetoclax in R/R DLBCL
NCT04572763
Acalabrutinib in CNSL
NCT04906902
Abemaciclib With or Without Atezolizumab for mCRPC
NCT04751929
Taking AIM at Breast Cancer
NCT04720209
Reducing Metabolic Dysregulation in Obese Latina Breast Cancer Survivors Using Physical Activity
NCT04717050
Phase Ia/Ib Talazoparib + Tazemetostat for mCRPC
NCT04846478
Ipilimumab With or Without Nivolumab in Relapsed/Refractory cHL
NCT04938232
The Effect of Electroacupuncture on Nerve Pain Caused by Chemotherapy (Chemotherapy-Induced Peripheral Neuropathy)
NCT04917796
Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma
NCT04850846
Safe Accelerated Venetoclax Escalation in CLL
NCT04843904
Intervention For AYAS With Cancer Risk Syndromes
NCT04323774
Digitally Enhanced Smoking Cessation for High Risk Smokers
NCT04691297
Niraparib + Dostarlimab In BRCA Mutated Breast Cancer
NCT04584255
Axi-cel in CNS Lymphoma
NCT04608487
Olaparib With Ceralasertib in Recurrent Osteosarcoma
NCT04417062
NeoVax With Nivolumab in Patients With Ovarian Cancer
NCT04024878
Post-treatment Surveillance in HPV+ Oropharyngeal SCC
NCT04965792
Neoantigen Vaccine Plus Locally Administered Ipilimumab and Systemic Nivolumab in Advanced Melanoma
NCT03929029
YES Study - Newly Diagnosed/Metastatic Intervention
NCT04379414
Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers
NCT04416568
MARGetuximab Or Trastuzumab (MARGOT)
NCT04425018
Ibrutinib + Venetoclax in Untreated WM
NCT04273139
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 181 |
| Phase 2 | 311 |
| Phase 3 | 14 |
| Phase 4 | 1 |
Therapeutic Areas
What is open in the Dana-Farber Cancer Institute pipeline
112 recruiting of 781 indexed (14% open); 449 completed (57%).
Phase mix: 15 late (III/IV) vs 492 early (I/II) (early-phase heavy).
Top condition: Breast Cancer (53 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Dana-Farber Cancer Institute: open-pipeline peers nationwide
Peers matched on 781 registered trials and 14% open enrollment, not the therapeutic-area sidebar.
Dana-Farber Cancer Institute sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 781 trials (± recruiting share)
- University of California, San Diego · 775 trials · 18% recruiting
- University of Chicago · 796 trials · 20% recruiting
- Medical University of South Carolina · 755 trials · 19% recruiting
- University of Utah · 818 trials · 17% recruiting
Sponsors near 14% open enrollment (± trial volume)
- The Cleveland Clinic · 14% recruiting · 688 trials
- Academic and Community Cancer Research United · 14% recruiting · 42 trials
- Adaptive Biotechnologies · 14% recruiting · 7 trials
- AgelessRx · 14% recruiting · 7 trials
Related
What to do with this Dana-Farber Cancer Institute page
781 registered trials is a research-attention snapshot, not an endorsement of Dana-Farber Cancer Institute or any single study.
- 112 of Dana-Farber Cancer Institute's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Breast Cancer is the condition Dana-Farber Cancer Institute studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Dana-Farber Cancer Institute pipeline card: 781 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.